Promising leukemia combo study pulled before starting
NCT ID NCT07428486
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to find safe doses of two experimental drugs (lisaftoclax and pelcitoclax) combined with standard FLAG chemotherapy for adults with T-cell acute lymphoblastic leukemia that returned or didn't respond to treatment. The trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FLAG CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to improve leukemia treatment in young adults
- New drug combo aims to boost survival in aggressive leukemia
- Experimental CAR-T therapy takes on stubborn blood disorder
- New CAR t-cell combo aims to control aggressive leukemia
- New cell therapy offers hope for tough blood cancers
- PET scans may reveal hidden leukemia spots before CAR t treatment